---
layout: default
title: Valine
parent: Low Evidence (L4-L5)
nav_order: 681
evidence_level: L4
indication_count: 10
---

# Valine
{: .fs-9 }

Tahap bukti: **L4** | Indikasi diramal: **10** 
{: .fs-6 .fw-300 }

---

## Isi kandungan
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Laporan penilaian ahli farmasi

</div>

# Valine: From Amino Acid Nutritional Supplementation to Sclerosing Cholangitis

## One-Sentence Summary

Valine is a branched-chain essential amino acid; no specific original indication text is available in the current dataset, though it is generally used in nutritional/parenteral amino acid formulations. The TxGNN model predicts a possible association with **Sclerosing Cholangitis**, but this is currently supported only by **0 clinical trials** and **2 publications**, neither of which directly demonstrates a therapeutic effect of valine on this condition.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in Malaysia registration data (general knowledge: essential amino acid used in nutritional/parenteral formulations) |
| Predicted New Indication | Sclerosing Cholangitis |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L4 |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 41 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available for valine in this evidence pack. Based on general pharmacological knowledge, valine is one of the three branched-chain amino acids (BCAA) and is a normal component of protein and nutritional/parenteral amino acid formulations; it has no established pharmacologic action against liver or biliary disease.

The supporting literature for sclerosing cholangitis is weak and indirect. One publication (PMID 39015781) is a Mendelian randomization study examining causal relationships between blood metabolites/metabolic pathways and cholestatic liver diseases (including primary sclerosing cholangitis); its abstract does not confirm valine specifically as a significant causal factor. The second publication (PMID 15790420) studies amino acid patterns and fatigue in primary biliary cirrhosis and primary sclerosing cholangitis, but its key finding concerns **tyrosine**, not valine.

Given the absence of interventional or clinical trial evidence, and that neither cited publication directly implicates valine as a therapeutic agent for sclerosing cholangitis, the mechanistic rationale for this prediction should be considered speculative and model-driven rather than evidence-driven at this stage.

> **Note on evidence quality across other predicted indications:** For several other TxGNN-predicted indications for valine (e.g., hyperthyroidism, resistance to thyroid hormone, hyperthyroxinemia, angle-closure glaucoma), the majority of retrieved literature consists of genetic mutation nomenclature artifacts — "Val" is the standard three-letter code for the amino acid valine, so searches surface papers about point mutations (e.g., V336M, L346V, Val53Ala) that are unrelated to valine as a therapeutic agent. This indicates a systematic text-matching issue in evidence retrieval for this candidate and warrants caution when interpreting literature counts for this drug more broadly.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [39015781](https://pubmed.ncbi.nlm.nih.gov/39015781/) | 2024 | Mendelian randomization | Frontiers in medicine | Investigated causal relationships between blood metabolites/metabolic pathways and cholestatic liver diseases (PBC/PSC); does not specifically confirm valine as a significant causal factor |
| [15790420](https://pubmed.ncbi.nlm.nih.gov/15790420/) | 2005 | Observational/Cohort | BMC gastroenterology | Examined amino acid patterns and fatigue in PBC/PSC patients; the significant finding relates to tyrosine, not valine |

---

## Malaysia Market Information

Aggregate registration data indicates 41 total product licenses in Malaysia with active ("Marketed"/Marketed) status. Itemized license numbers, product names, dosage forms, and approved indication text were not returned in the current data pull (all fields empty), so a per-license table cannot be produced at this time.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Data gap note:** TFDA/NPRA label warnings and contraindications for valine (DG001) are currently missing and are flagged as **Blocking** — this must be resolved before the candidate can enter Stage S1 safety review.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Evidence for a valine–sclerosing cholangitis association is minimal: no clinical trials and only two publications, neither of which directly supports valine as causally or therapeutically relevant to the disease. Combined with unresolved Blocking-level safety data gaps (label warnings/contraindications) and missing MOA data, the candidate does not currently meet the threshold to advance beyond initial screening (Stage S0).

**To proceed, the following is needed:**
- TFDA/NPRA label warnings and contraindications (currently Blocking data gap, DG001)
- Confirmed mechanism of action (MOA) data from DrugBank or other authoritative source (DG002)
- Targeted mechanistic or preclinical studies specifically evaluating valine (not amino acids/BCAA generally) in cholestatic/sclerosing cholangitis models
- Re-run literature searches with disambiguation of "valine" from genetic mutation nomenclature ("Val" amino acid codes) to avoid false-positive evidence counts in this and related predicted indications
## Penafian

Kandungan ini adalah untuk tujuan penyelidikan sahaja dan bukan nasihat perubatan.
Pengesahan klinikal diperlukan sebelum sebarang aplikasi klinikal.

---

